Patents by Inventor Anna Quattropani

Anna Quattropani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190000812
    Abstract: The invention provides pharmaceutical compositions comprising a compound of formula (I) or (II) and an additional therapeutic agent Also provided is the HCI salt and crystalline form of the compound of formula (I). The compounds inhibit the prostaglandin F receptor (PGF2alpha) and thus useful in the treatment of disorders such as preterm labor at the early gestational stage.
    Type: Application
    Filed: January 4, 2017
    Publication date: January 3, 2019
    Inventors: Patrick Naxos PAGE, Matthias SCHWARZ, Catherine JORAND-LEBRUN, Anna QUATTROPANI, Vincent POMEL, Ernest LOUMAYE, Oliver POHL, Jean-Pierre GOTTELAND
  • Publication number: 20180215770
    Abstract: The present invention provides compounds of Formula (I) used as Amyloid beta lowering agent for the treatment of neurodegenerative diseases.
    Type: Application
    Filed: December 1, 2017
    Publication date: August 2, 2018
    Inventors: Anna Quattropani, Dominique Swinnen
  • Publication number: 20180201591
    Abstract: The invention provides ?-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1?-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorphs thereof, that can be used to inhibit prostaglandin F receptor. The invention further encompasses methods of treating disorders such as pre-term labor at the early gestational stage by the administration of these substances to a patient in need of treatment.
    Type: Application
    Filed: October 10, 2017
    Publication date: July 19, 2018
    Inventors: Patrick Naxos PAGE, Matthias SCHWARZ, Catherine JORAND-LEBRUN, Anna QUATTROPANI, Vincent POMEL
  • Patent number: 9932354
    Abstract: The present invention provides compounds of Formula (I) used as Amyloid beta lowering agent for the treatment of neurodegenerative diseases.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: April 3, 2018
    Assignee: Ares Trading S.A.
    Inventors: Anna Quattropani, Dominique Swinnen
  • Patent number: 9834528
    Abstract: The invention provides ?-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1?-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorph s thereof, that can be used to inhibit prostaglandin F receptor. The invention further encompasses methods of treating disorders such as pre-term labor at the early gestational stage by the administration of these substances to a patient in need of treatment.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: December 5, 2017
    Assignee: Merck Serono S.A.
    Inventors: Patrick Naxos Page, Matthias Schwarz, Catherine Jorand-Lebrun, Anna Quattropani, Vincent Pomel
  • Publication number: 20170298082
    Abstract: The disclosure relates to compounds of formula (I) useful in the treatment of tauopathies and Alzheimer's disease wherein A, R, W, Q, n, and m are described herein.
    Type: Application
    Filed: August 27, 2015
    Publication date: October 19, 2017
    Inventors: Anna QUATTROPANI, Santosh S. KULKARNI, Awadut Gajendra GIRI
  • Publication number: 20170190677
    Abstract: The invention provides ?-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1?-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorph s thereof, that can be used to inhibit prostaglandin F receptor. The invention further encompasses methods of treating disorders such as pre-term labor at the early gestational stage by the administration of these substances to a patient in need of treatment.
    Type: Application
    Filed: August 8, 2016
    Publication date: July 6, 2017
    Inventors: Patrick Naxos PAGE, Matthias SCHWARZ, Catherine JORAND-LEBRUN, Anna QUATTROPANI, Vincent POMEL
  • Patent number: 9527853
    Abstract: The present invention provides fused bicyclic triazole derivatives of Formula (I) useful as gamma secretase modulators (GSM), for the treatment of Alzheimer's disease and related diseases.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: December 27, 2016
    Assignee: Ares Trading S.A.
    Inventors: Ben Whittaker, Chris Steele, David Hardick, Dale Mitchell, Vincent Pomel, Anna Quattropani, Dirk Beher
  • Patent number: 9505769
    Abstract: The present invention provides compounds of Formula (I) as M1 receptor positive allosteric modulators for the treatment of diseases mediated by the muscarinic M1 mediator.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: November 29, 2016
    Assignee: Asceneuron SA
    Inventors: Anna Quattropani, Santosh S. Kulkarni, Kathiravan Murugesan, Joydeep Banerjee
  • Patent number: 9447055
    Abstract: The invention provides ?-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1?-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorphs thereof, that can be used to inhibit prostaglandin F receptor. The invention further encompasses methods of treating disorders such as pre-term labor at the early gestational stage by the administration of these substances to a patient in need of treatment.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: September 20, 2016
    Assignee: Merck Serono S.A.
    Inventors: Patrick Naxos Page, Matthias Schwarz, Catherine Jorand-Lebrun, Anna Quattropani, Vincent Pomel
  • Patent number: 9403835
    Abstract: The present invention provides compounds of Formula (I) as M1 receptor positive allosteric modulators for the treatment of diseases mediated by the muscarinic M1 mediator.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: August 2, 2016
    Assignee: Ares Trading S.A.
    Inventors: Dominique Swinnen, Cyril Montagne, Vincent Pomel, Anna Quattropani, Jerome Molette, Patrick Gerber
  • Publication number: 20160137648
    Abstract: The present invention provides compounds of Formula (I) as M1 receptor positive allosteric modulators for the treatment of diseases mediated by the muscarinic M1 mediator.
    Type: Application
    Filed: June 12, 2014
    Publication date: May 19, 2016
    Applicant: ASCENEURON SA
    Inventors: ANNA QUATTROPANI, SANTOSH S. KULKARNI, KATHIRAVAN MURUGESAN, JOYDEEP BANERJEE
  • Patent number: 9233982
    Abstract: The present invention provide compounds of Formula (I) used as BACE inhibitors for the treatment of neurodegenerative diseases.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: January 12, 2016
    Assignee: Ares Trading S.A.
    Inventors: Anna Quattropani, Dominique Swinnen
  • Patent number: 9150561
    Abstract: The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neturodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: October 6, 2015
    Assignee: MERCK SERONO S.A.
    Inventors: Anna Quattropani, Thomas Rueckle, Matthias Schwarz, Jerome Dorbais, Wolfgang Sauer, Christophe Cleva, Gwenaelle Desforges
  • Publication number: 20150183790
    Abstract: The present invention provides fused bicyclic triazole derivatives of Formula (I) useful as gamma secretase modulators (GSM), for the treatment of Alzheimer's disease and related diseases.
    Type: Application
    Filed: June 14, 2013
    Publication date: July 2, 2015
    Applicant: Merck Patent GmbH
    Inventors: Ben Whittaker, Chris Steele, David Hardick, Dale Mitchell, Vincent Pomel, Anna Quattropani, Dirk Beher
  • Publication number: 20150175628
    Abstract: The present invention provides compounds of Formula (I) used as Amyloid beta lowering agent for the treatment of neurodegenerative diseases.
    Type: Application
    Filed: May 23, 2013
    Publication date: June 25, 2015
    Applicant: Merck Patent GmbH
    Inventors: Anna Quattropani, Dominique Swinnen
  • Patent number: 9029405
    Abstract: The present invention provides compounds of Formula (I), as selective S1P1 inhibitors, as well as their use for treating multiple sclerosis and other diseases.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: May 12, 2015
    Assignee: Merck Serono S.A.
    Inventors: Agnes Bombrun, Anna Quattropani, Jerome Gonzalez, Jerome Dorbais, Chris Knight, Charles Baker-Glenn
  • Publication number: 20150111882
    Abstract: The present invention provide compounds of Formula (I) used as BACE inhibitors for the treatment of neurodegenerative diseases.
    Type: Application
    Filed: May 10, 2013
    Publication date: April 23, 2015
    Applicant: Ares Trading S.A.
    Inventors: Anna Quattropani, Dominique Swinnen
  • Publication number: 20150018343
    Abstract: The present invention provides compounds of Formula (I) as M1 receptor positive allosteric modulators for the treatment of diseases mediated by the muscarinic M1 mediator.
    Type: Application
    Filed: November 30, 2012
    Publication date: January 15, 2015
    Inventors: Dominique Swinnen, Cyril Montagne, Vincent Pomel, Anna Quattropani, Jerome Molette, Patrick Gerber
  • Patent number: 8889668
    Abstract: The invention relates to compounds of formula (I): wherein R1, R2, Ra, Rb, Rc and W, have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.
    Type: Grant
    Filed: December 12, 2012
    Date of Patent: November 18, 2014
    Assignee: Merck Serono SA
    Inventors: Cyril Montagne, Anna Quattropani, Wolfgang Sauer, Agnes Bombrun